• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
NXTC

NXTC

NextCure, Inc.

NASDAQHealthcareBiotechnologyUS

USD3.15

-0.25 (-7.35%)

Rating:C+

Company Profile

CEO

Michael S. Richman

IPO Date

2019-05-09

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$3.32

Prev. Close

$3.40

Day Low

$3.06

Day High

$3.48

52W Low

$2.83

52W High

$15.74

Market Cap

$0.01B

Volume

0.13M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

24.8%

Avg Negative

1.0%

Avg Neutral

74.1%

News Feed

NextCure Launches Early-Stage Study For NC762 In Solid Tumor Settings

Benzinga·7/7/2021·↑ positive

NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors

GlobeNewsWire·7/6/2021·↑ positive

NextCure's Immunomedicine NC410 Shows Promising Anti-Cancer Activity In Preclinical Studies

Benzinga·6/22/2021·↑ positive

NextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410

GlobeNewsWire·6/21/2021·↑ positive

NextCure to Present at the JMP Securities Life Sciences Conference

GlobeNewsWire·6/10/2021·↑ positive

NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewsWire·5/19/2021·↑ positive

NextCure Reports First Quarter 2021 Financial Results

GlobeNewsWire·5/6/2021·↑ positive

NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR) Annual Meeting 2021

GlobeNewsWire·4/10/2021·↑ positive

NextCure to Present at the 20th Annual Needham Virtual Healthcare Conference

GlobeNewsWire·4/7/2021·↑ positive

REMINDER: NextCure to Host Virtual R&D Update Event on March 4, 2021

GlobeNewsWire·3/2/2021·↑ positive